Compugen (NASDAQ:CGEN) released its quarterly earnings results on Wednesday. The biotechnology company reported ($0.18) EPS for the quarter, Morningstar.com reports.
Compugen (CGEN) opened at $3.25 on Thursday. The stock has a market cap of $168.30, a PE ratio of -4.58 and a beta of 0.68. Compugen has a 12-month low of $2.25 and a 12-month high of $5.40.
Institutional investors and hedge funds have recently made changes to their positions in the stock. Taylor Frigon Capital Management LLC bought a new position in Compugen in the 4th quarter valued at about $707,000. Ark Investment Management LLC grew its position in Compugen by 104.1% in the 2nd quarter. Ark Investment Management LLC now owns 560,103 shares of the biotechnology company’s stock valued at $2,128,000 after buying an additional 285,653 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. bought a new position in Compugen in the 4th quarter valued at about $2,381,000. Benjamin F. Edwards & Company Inc. grew its position in Compugen by 35.4% in the 4th quarter. Benjamin F. Edwards & Company Inc. now owns 85,300 shares of the biotechnology company’s stock valued at $213,000 after buying an additional 22,305 shares in the last quarter. Finally, Renaissance Technologies LLC grew its position in Compugen by 26.5% in the 4th quarter. Renaissance Technologies LLC now owns 340,008 shares of the biotechnology company’s stock valued at $850,000 after buying an additional 71,308 shares in the last quarter. Hedge funds and other institutional investors own 23.06% of the company’s stock.
Several research firms have recently commented on CGEN. Zacks Investment Research lowered shares of Compugen from a “buy” rating to a “hold” rating in a research report on Monday, January 22nd. ValuEngine lowered shares of Compugen from a “sell” rating to a “strong sell” rating in a research report on Sunday, December 31st.
COPYRIGHT VIOLATION NOTICE: This news story was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this news story on another website, it was illegally stolen and reposted in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.dispatchtribunal.com/2018/02/22/compugen-cgen-releases-quarterly-earnings-results.html.
Compugen Ltd. is a therapeutic discovery company. The Company focuses on infrastructure to discover drug targets and develop therapeutics. The Company is engaged in the research, development and commercialization of therapeutic and product candidates. The Company’s pipeline primarily consists of early and preclinical stage immuno-oncology programs based on drug targets discovered by the Company, primarily immune checkpoint and myeloid protein target candidates.
Receive News & Ratings for Compugen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Compugen and related companies with MarketBeat.com's FREE daily email newsletter.